A new paradigm for metabolic health
Elaphron EL-924: Redefining the Treatment of Obesity, Insulin Resistance, and Metabolic Disease by Targeting Their Biological Roots
Lead
BT-924
Stage
Preclinical
Modality
Non-systemic
Focus
Obesity
What We Do
First-in-class therapies through intestinal signaling.
Elaphron develops therapies for metabolic disease that work through the gastrointestinal tract. Our lead program, BT-924, is designed to act locally in the proximal small intestine to regulate systemic metabolism.
Lead program
BT-924
Modality
Non-systemic
Stage
Preclinical
Why It Matters
Obesity is a global health challenge.
Hundreds of millions of people are affected worldwide. Despite recent advances, current therapies still face significant limitations in long-term adherence, tolerability, and metabolic outcomes.
We believe the next breakthrough lies in addressing the underlying biology of metabolic regulation.
Vision
EL 924 is designed to creat effective alternative that addresses key limitations of Incretine Based therapies (GLP-1/GIP) like adherence challenges, reliance on appetite suppression, lean mass loss, GI adverse effects and high cost allowing to better address obesity and insulin resistance epidemic on population level
Mission
Our Approach
Modulating proximal intestinal signaling.
Non-systemic
Local activity, minimal systemic exposure
Mechanistically distinct
Set point–driven, not appetite-suppression
Combinable
Designed to complement existing therapies
The Science
Targeting intestinal nutrient sensing.
